In pharmaceuticals and biotech, contracts are not back-office paperwork; they are the operating system that allows a drug programme to move at all. Research, manufacturing, distribution and even regulatory progress are often carried out by outside partners, which means the company’s real control layer sits in the agreements that govern those relationships.

That is why contract management in life sciences carries consequences that are unusually high. The NIH-funded CTSA Contracts Processing Study found that clinical trial agreements take more than 100 days on average to negotiate, while every day of delay can cost sponsors between $600,000 and $8 million in lost potential revenue. Applied Clinical Trials has also reported that nearly half of study delays are linked to contracting bottlenecks. In a sector where timing can shape funding, trial momentum and eventual market entry, those delays are more than administrative friction.

The issue is especially acute because so much of the work is outsourced. CROs run trials, CMOs and CDMOs handle manufacturing, and distributors help carry products into the market. Pharma Guide has noted that outsourcing across CRO, CDMO and CMO services has become a defining feature of the industry, driven by higher R&D costs, tighter timelines and the need for specialist capabilities. Contracko similarly says pharmaceutical and biotech teams now need to monitor clinical milestones, regulatory deadlines and intellectual property rights across a wide range of contract types, including trial agreements, licensing deals and supply contracts.

Crowell & Moring says it has worked on more than 10,000 clinical trial agreements, underscoring how common and operationally important these contracts have become. The firm says the challenge is to move quickly without losing sight of intellectual property, regulatory compliance and risk allocation. That balance is difficult for larger drugmakers; for emerging biotechs, it can be overwhelming.

Contract Pharma has said emerging biopharma companies account for 63% of trial starts, yet many still lack in-house contracting resources. These businesses often have lean teams and multiple live dependencies at once: a CRO agreement in one country, a manufacturing contract in another, a licensing negotiation tied to royalties, and a stack of regulatory documents all moving on different timelines. When those agreements are scattered, the result is usually slower decisions and weaker visibility.

The practical need, then, is not simply a place to store contracts. Life sciences teams need software that can follow the links between related agreements, surface key dates, search across the full portfolio and extract important terms from very different document types. A delay in one agreement can affect enrollment, manufacturing, launch planning and compliance work downstream. For a legal or operations team trying to keep a development programme moving, that chain of impact has to be visible.

That is where modern contract management platforms are trying to position themselves. ContractSafe says its system is designed to help life sciences teams manage contracts from intake to renewal, with fast setup, AI extraction, unlimited users and support aimed at smaller organisations that need immediate utility rather than a long implementation cycle. The company’s pitch reflects a broader reality in pharma: if the external partnerships are what make the science possible, then the contracts that govern them are what make the business work.

Source: Noah Wire Services